J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 9, Number 7, July 2017, pages 567-572

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes

Figure

Figure 1. Assessment, randomization, and follow-up of the study patients.

Tables

**Table 1.** Clinical and Laboratory Characteristics at Baseline, 12 Weeks, and 24 Weeks of Treatment With Vildagliptin or Alogliptin
	Vildagliptin			Alogliptin
	Baseline	12 week	24 week Vildagliptin → sitagliptin	Baseline	12 week	24 week Alogliptin → sitagliptin
*P = 0.05, data compared with baseline values using the t-test. †P = 0.05, data compared with 12 weeks values using the t-test.
Age	63.2 ± 13.5			65.1 ± 12.0	60.4 ± 12.9
Male	10			9
Female	9			7
Height (cm)	162.8 ± 10.1			159.3 ± 9.5
Weight (kg)	65.4 ± 13.3	68.6 ± 13.2	67.2 ± 16.3	59.4 ± 11.2	60.4 ± 12.9	60.2 ± 12.1
BMI (kg/m²)	24.6 ± 4.4			23.1 ± 3.5
PG (mg/dL)	175.5 ± 54.4	179.1 ± 73.4	172.2 ± 54.5	175.4 ± 50.9	195.3 ± 55.0	189.3 ± 32.4
HbA1c (%)	8.0 ± 0.5	8.0 ± 0.8	8.3 ± 0.7	8.0 ± 0.5	8.31 ± 0.7*	8.0 ± 0.8†

**Table 2.** The Response Rate (RR) of Achieving the Goal Proportion of Patients Who Achieved Target Glycemic Control
	Alogliptin (N = 16)	Vildagliptin (N = 19)	P value
Proportion of patients who achieved HbA1c < 7.0% at 12 weeks	1 (6.3%)	2 (10.5%)	1.000
Proportion of patients who achieved PG < 130 mg/dL at 12 weeks	1 (6.3)	7 (36.8%)	0.047
Change to sitagliptin	13 (81.2%)	15 (78.9%)
Proportion of patients who achieved HbA1c < 7.0% at 24 weeks	3 (9.1%)
Proportion of patients who achieved PG < 130 mg/dL at 24 weeks	1 (3.0%)